MA50657A - Formulations de niraparib - Google Patents

Formulations de niraparib

Info

Publication number
MA50657A
MA50657A MA050657A MA50657A MA50657A MA 50657 A MA50657 A MA 50657A MA 050657 A MA050657 A MA 050657A MA 50657 A MA50657 A MA 50657A MA 50657 A MA50657 A MA 50657A
Authority
MA
Morocco
Prior art keywords
niraparib formulations
niraparib
formulations
Prior art date
Application number
MA050657A
Other languages
English (en)
Inventor
Simon Mcgurk
Padma Narayan
Aleksandar Rajlic
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA50657A publication Critical patent/MA50657A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050657A 2017-09-26 2018-09-26 Formulations de niraparib MA50657A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762563535P 2017-09-26 2017-09-26

Publications (1)

Publication Number Publication Date
MA50657A true MA50657A (fr) 2020-08-05

Family

ID=63858161

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050657A MA50657A (fr) 2017-09-26 2018-09-26 Formulations de niraparib

Country Status (17)

Country Link
US (2) US11730725B2 (fr)
EP (1) EP3687505A1 (fr)
JP (1) JP7269227B2 (fr)
KR (1) KR20200058496A (fr)
CN (1) CN111278433A (fr)
AU (2) AU2018341479B2 (fr)
BR (1) BR112020006039A2 (fr)
CA (1) CA3076907A1 (fr)
CL (1) CL2020000747A1 (fr)
EA (1) EA202090573A1 (fr)
IL (1) IL273282A (fr)
MA (1) MA50657A (fr)
MX (1) MX2020003760A (fr)
PH (1) PH12020550341A1 (fr)
SG (1) SG11202002113TA (fr)
TW (1) TWI843707B (fr)
WO (1) WO2019067634A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
EP3615513B1 (fr) 2017-04-24 2022-07-20 Tesaro, Inc. Procédés de fabrication de niraparib
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
EP3697442A4 (fr) 2017-09-30 2021-07-07 Tesaro, Inc. Polythérapies pour le traitement du cancer
CA3076859A1 (fr) 2017-10-06 2019-04-11 Tesaro, Inc. Polyrherapies et leurs utilisations
WO2021224469A1 (fr) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Traitements du cancer de la prostate au moyen d'associations d'acétate d'abiratérone et de niraparib
EP4167967A1 (fr) * 2020-06-19 2023-04-26 GlaxoSmithKline Intellectual Property (No.2) Limited Formulation comprenant du daprodustat
CA3199341A1 (fr) * 2020-11-20 2022-05-27 Nikolaos DRAKOULIS Formulation de chlorure d'ammonium d'aide a la defense naturelle humaine contre des virus
WO2023159066A1 (fr) 2022-02-15 2023-08-24 Tesaro, Inc. Utilisation de niraparib pour le traitement du cancer du cerveau
WO2024124182A1 (fr) * 2022-12-09 2024-06-13 Olema Pharmaceuticals, Inc. Formes galéniques d'un antagoniste du récepteur des œstrogènes

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606337D0 (en) 1996-03-26 1996-05-29 Freeman Reginald E Rheometer
AR030630A1 (es) 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
AR052319A1 (es) 2004-10-29 2007-03-14 Kalypsys Inc Compuestos biciclicos sustituidos por sulfonilo en funcion de moduladores del ppar
GB0700432D0 (en) 2007-01-10 2007-02-21 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2647545C (fr) 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Utilisation de derives de benzotriazole et d'indazole amide substitue comme inhibiteurs de la poly(adp-ribose)polymerase (parp)
WO2008043024A2 (fr) * 2006-10-04 2008-04-10 Kalypsys, Inc. Formulation pharmaceutique orale comprenant un sulfonyle bicyclique modulateur de ppar pour le traitement d'une maladie
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
NZ579098A (en) 2007-01-16 2012-07-27 Bipar Sciences Inc Formulations for cancer treatment
CA2702429A1 (fr) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Forme cristalline l du 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
SG178852A1 (en) 2009-08-26 2012-04-27 Cephalon Inc Novel forms of a multicyclic compound
CA2779052A1 (fr) 2012-05-31 2013-11-30 Pharmascience Inc. Composition pharmaceutique d'antecavir et processus de fabrication
DK2928865T3 (en) 2012-12-07 2018-06-18 Merck Sharp & Dohme BIOCATALYTIC TRANSAMINATION PROCEDURE
WO2014088983A1 (fr) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Arylation n-2 régiosélective d'indazoles
US11491154B2 (en) * 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
US9191894B2 (en) 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
CN106458935B (zh) * 2014-01-05 2019-05-28 华盛顿大学 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途
WO2015164161A1 (fr) 2014-04-22 2015-10-29 Calitor Sciences, Llc Composés pyrazolone bicycliques et procédés d'utilisation
WO2015164586A1 (fr) 2014-04-23 2015-10-29 The Brigham And Women's Hospital, Inc. Ciblage de parp1 pour le traitement de la sclérose tubéreuse de bourneville et de cancers
EP3148336B1 (fr) * 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. L'éribuline et des inhibiteurs de la poly(adp-ribose) polymérase (parp) en tant que que polythérapie pour le traitement du cancer
BR112017000865A2 (pt) * 2014-08-22 2017-12-05 Clovis Oncology Inc comprimidos de rucaparibe de concentração de dosagem alta
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
SG10202103458QA (en) 2015-04-06 2021-05-28 Janssen Pharmaceutica Nv Compositions containing ibrutinib
KR102688052B1 (ko) 2015-07-02 2024-07-25 아세르타 파마. 비.브이. (S)-4-(8-아미노-3-(1-(부트-2-이노일)피롤리딘-2-일)이미다조[1,5-a]피라진-1-일)-N-(피리딘-2-일)벤즈아마이드의 고체 형태 및 제제
EP3328896A4 (fr) 2015-07-31 2019-08-07 University of Florida Research Foundation, Inc. Cellules souches hématopoïétiques en thérapie combinatoire comprenant des inhibiteurs de points de contrôle immunitaires contre le cancer
AU2017208472B2 (en) 2016-01-19 2022-09-01 Janssen Pharmaceutica Nv Formulations/compositions comprising a BTK inhibitor
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
KR102510996B1 (ko) 2016-06-29 2023-03-16 테사로, 인코포레이티드 난소암의 치료 방법
CN106496187A (zh) 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (fr) * 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
KR102606252B1 (ko) 2017-01-09 2023-11-23 테사로, 인코포레이티드 항-pd-1 항체로 암을 치료하는 방법
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
MX2019011491A (es) 2017-03-27 2020-01-23 Tesaro Inc Formulaciones de niraparib.
EP3615513B1 (fr) 2017-04-24 2022-07-20 Tesaro, Inc. Procédés de fabrication de niraparib
EP3615572A1 (fr) 2017-04-27 2020-03-04 Tesaro Inc. Agents anticorps dirigés contre la protéine codée par le gène d'activation des lymphocytes 3 (lag-3) et utilisations associées
MA48637A (fr) 2017-05-09 2021-03-17 Merck Sharp & Dohme Polythérapies pour le traitement du cancer
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
EP3697442A4 (fr) 2017-09-30 2021-07-07 Tesaro, Inc. Polythérapies pour le traitement du cancer
CA3076859A1 (fr) 2017-10-06 2019-04-11 Tesaro, Inc. Polyrherapies et leurs utilisations
WO2019133697A1 (fr) 2017-12-27 2019-07-04 Tesaro, Inc. Méthodes de traitement du cancer
WO2019152989A1 (fr) 2018-02-05 2019-08-08 Tesaro, Inc Formulations pédiatriques de niraparib et procédés de traitement pédiatrique

Also Published As

Publication number Publication date
AU2018341479B2 (en) 2022-02-17
US20240082231A1 (en) 2024-03-14
EA202090573A1 (ru) 2020-09-07
US20200289494A1 (en) 2020-09-17
CN111278433A (zh) 2020-06-12
JP7269227B2 (ja) 2023-05-08
SG11202002113TA (en) 2020-04-29
US11730725B2 (en) 2023-08-22
WO2019067634A1 (fr) 2019-04-04
TWI843707B (zh) 2024-06-01
KR20200058496A (ko) 2020-05-27
TW201927304A (zh) 2019-07-16
EP3687505A1 (fr) 2020-08-05
MX2020003760A (es) 2020-07-29
JP2020535158A (ja) 2020-12-03
IL273282A (en) 2020-04-30
PH12020550341A1 (en) 2021-02-15
AU2022200520A1 (en) 2022-02-17
CA3076907A1 (fr) 2019-04-04
BR112020006039A2 (pt) 2020-10-06
AU2018341479A1 (en) 2020-04-16
CL2020000747A1 (es) 2020-09-25

Similar Documents

Publication Publication Date Title
DK3688162T3 (da) Formuleringer
DK3731771T3 (da) V462033dk00
DE202018003363U8 (de) Handgelenkssphygmomanometer
MA50657A (fr) Formulations de niraparib
CL2018000524S1 (es) Golilla
DK3351526T3 (da) Diisopentylterephthalat
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
DK3568655T3 (da) Rekuperator
DK3651736T3 (da) Langtidsvirkende formuleringer
DK3612237T3 (da) Genterapi
DK3568506T3 (da) Offeranode
MA50068A (fr) Formulations de copanlisib
DK3576686T3 (da) Brokbind
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse
DK3576718T3 (da) Pastil
FI11704U1 (fi) Liittopuujärjestely
TR201503831A2 (tr) Antimipertansif kombinasyon formülasyonları
DK3510051T3 (da) Carboxylalkylchitosan
DK3391733T3 (da) Ballepresse
ES1205411Y (es) Maleta-Gaveta
ES1198359Y (es) Columbario
FI11529U1 (fi) Ontelolaatan kannake
DK3645955T3 (da) Buffertank
DK3401461T3 (da) Falsetagtegl